Moderna confirmed this Sunday that a third dose of its coronavirus vaccine will be necessary to reinforce immunization against the emergence of new variants. Weeks ago, Pfizer spoke in the same direction regarding the application of its formula, a strategy that is evaluated by different laboratories around the world due to the uncertainty generated by the future of the pandemic.
In an interview published this Sunday by the French newspaper Sunday Newspaper, the CEO of Moderna, Frenchman Stéphane Bancel, stated that a third booster dose will have to be given to people who have already been vaccinated, starting “since the end of the (European) summer” with risk groups that were inoculated at the beginning of the year, and in particular with people living in residences.
The urgency, Bancel warned, is due to the fact that “Two or three months of delay would suppose numerous hospitalizations and deaths”.
“All adults, even young people” will have to receive a third dose “to protect unvaccinated fragile people” in the name of the precautionary principle, explained the specialist. This is because while Moderna’s vaccine is considered to offer immunity for a period of one to three years, “the arrival of variants increases the level of threat.”
Bancel also announced that at the beginning of June the laboratory will present a request for authorization to the European Medicines Agency (EMA) so that its vaccine can be used for adolescents between 12 and 17 years old. In his opinion, “the ideal” would be to protect these adolescents “before the end of August”.
The rush to cover the majority of the population with vaccines, said the expert, is due to the fact that “If it is not massively vaccinated, the risk of a fourth wave cannot be ruled out.”
So far, 90 million people have received both doses of Moderna. According to the CEO, Moderna could produce 3 billion doses per year. That figure, added to the 4 billion of doses that you plan to manufacture Pfizer-BioNTechIt would be enough to vaccinate all the world’s inhabitants with one dose, Bancel said.
In this Sunday’s interview, Moderna’s representative reiterated his criticism of the European Union for its “lack of anticipation” in the first months of the pandemic to work with laboratories on vaccines. In the case of Moderna, for example, the contract was only signed in November.